Boston Scientific Corporation (BSX) fair value analysis
S&P 500 · Updated 2026-10-19
BSX price how computed
Forward Fair Value verdict
UndervaluedBSX is trading at more than a 25% discount to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $42.73
- Sector
- Healthcare
- 12-month range
- $41.58–$104.98
- Market cap
- $61.9B
- From 52-week high
- -59.3%
- Shares outstanding
- 1.45B
- Rank in Healthcare by discount to fair value
- #2 of 108
Last price is our 2026-10-19 weekly price; the chart runs through 2026-10-16.
Boston Scientific Corporation is a medical device manufacturer that develops, produces, and markets products used in interventional medicine, including devices for cardiovascular, gastroenterology, urology, and oncology applications. The company operates globally across multiple regions including North America, Europe, and Asia-Pacific.
BSX currently ranks #2 of 108 Healthcare stocks by discount to fair value. It has screened as Undervalued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $61.9B
- P/E (trailing)
- 13x
- Revenue (TTM)
- $21B
- Net margin
- 17.5%
- EPS (TTM)
- $3.21
- Gross margin
- 70.7%
- Debt / equity
- 0.51
- Revenue growth (3-yr avg)
- 18.1%
- Shares outstanding
- 1.45B
Derived indicators how computed
- Quality grade
- A
- Margin trend
- Expanding
- 52-week position
- The bottom quarter of its range
- DCF cross-check
- Overvalued
Technicals how computed
- RSI (14-day)
- 57 · neutral
- 50-day average
- $46.09
- 200-day average
- $59.10
- Moving-average state
- 50-day below 200-day (death cross state); price below both averages
Earnings how computed
- Next earnings report
- 2026-10-28 (pre-market)
- Last 8 quarters vs consensus
- 8 beat, 0 missed
- Quarter by quarter
- 2026-06 ▲ beat (+3.6%)
2026-03 ▲ beat (+1.3%)
2025-12 ▲ beat (+2.6%)
2025-09 ▲ beat (+5.6%)
2025-06 ▲ beat (+2.7%)
2025-03 ▲ beat (+11.9%)
2024-12 ▲ beat (+6.1%)
2024-09 ▲ beat (+6.8%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 25 buy · 6 hold · 0 sell (31 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $59.2
- Target vs last price
- +38.5%
What our data shows for BSX
- Our model validated 17 trailing price-to-earnings windows for BSX, built from quarterly earnings records.
- Shares are trading in the lower third of their 12-month price range of $41.58–$104.98.
- The 14-day relative strength index sits at a neutral 57.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for BSX
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent BSX news
TickrTrends' derived news-sentiment signal for BSX is currently leaning positive, computed from recent coverage.
- Vertex Pharmaceuticals (VRTX) Expands Board to Eleven Members with Appointment of Former Boston Scientific CFO Daniel Brennan (gurufocus.com, 2026-10-21)
TickrTrends take: Boston Scientific (BSX) operates in the Healthcare sector where executive talent and leadership changes at competing firms can signal industry-wide shifts in strategy and capital allocation. The appointment of a former Boston Scientific CFO to Vertex Pharmaceuticals' board represents the movement of deep healthcare operational expertise to a competitor, which may reflect broader competitive dynamics within the sector. For investors monitoring BSX's current undervalued status, tracking how leadership and board composition at peer companies evolve can provide context for understanding relative management quality and strategic positioning within healthcare. - Boston Scientific: A Better Valuation, But The Turnaround Needs Proof (NYSE:BSX) (seekingalpha.com, 2026-10-16)
TickrTrends take: Boston Scientific trades at a valuation level that TickrTrends currently classifies as undervalued within the Healthcare sector, suggesting the market may not be fully pricing in the company's potential recovery. The headline's focus on valuation improvement indicates that while the stock has become more attractive on price metrics, investors should monitor whether the company can deliver operational results that justify this improved valuation. For valuation-focused investors, the key will be tracking whether Boston Scientific's business performance materializes to support the current discount to intrinsic value estimates. - Stryker (SYK) vs Boston Scientific (BSX): Which is a Better Stock to Buy? (insidermonkey.com, 2026-10-07)
TickrTrends take: Boston Scientific trades at a valuation that TickrTrends currently assesses as undervalued within the Healthcare sector, making it relevant to comparison discussions with peers like Stryker. A valuation-focused reader should monitor whether BSX's current pricing reflects genuine market inefficiency or temporary sector conditions, as direct comparisons between competing medical device companies often help clarify relative value opportunities. The undervalued designation suggests the market may not be fully pricing BSX's operational performance or growth prospects relative to its fundamentals.
More BSX news
- Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029 (manilatimes.net, 2026-10-01)
- NeurAxis Positions for Next Phase of Commercial Growth with Appointment of Craig Blanchard as Chief Commercial Officer (manilatimes.net, 2026-09-29)
What people are saying
Follow the BSX conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — BSX's relative strength index moved out of oversold territory into neutral range this week, suggesting reduced downward momentum in the Healthcare sector stock. The current valuation assessment remains Undervalued, indicating the stock may trade below its estimated fair value based on TickrTrends' derived indicators.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is BSX stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), BSX is trading at more than a 25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.
What is BSX's TickrTrends verdict?
BSX's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.
How does BSX compare to other Healthcare stocks?
BSX ranks #2 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is BSX overbought or oversold?
BSX's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does BSX report earnings next?
BSX's next earnings report is scheduled for 2026-10-28 (pre-market), per the published earnings calendar.
Does BSX usually beat earnings estimates?
Over its last 8 reported quarters BSX beat the consensus estimate 8 times and missed 0 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about BSX?
Of 31 analysts covering BSX, 25 rate it a buy, 6 a hold and 0 a sell - buy-leaning, with a consensus price target of $59.2 (+38.5% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
BSX vs ADMA · BSX vs ALGN · BSX vs ANIP · BSX vs ASTH · BSX vs AZN